With increased capital flow, and companies looking to go further with longer term aspirations, is the pharma deal-making landscape getting tougher? With more competition than ever before, better funded companies and higher valuations, is making win-win deals harder for international pharma? Pharma BD&L heads discuss how evolving industry and investment dynamics are impacting pharma’s approach, and how Nordic innovation across the healthcare spectrum fits into their business development and deal-making strategies.

• The impact of evolving investment dynamics on pharma partnering and deal-making strategies
• COVID as an accelerator – how dramatically has the pandemic affected pharma’s partnering and deal-making strategies? Are deal analysis and reviews being done more quickly and efficiently and will this continue?
• What challenges does the common trend of relatively early-listing of companies in the Nordics have on partnering and M&A deals?
• What are Pharma looking for in Nordic science technology and innovation?

Karen McGurk, Executive Director Transactions, MSD
Miriam Frieden, VP S&E, Novo Nordisk
James Stamatis, Vice President, Head of Business Development and Acquisitions, AbbVie
Tahera Kan, VP Early Innovation Partnering, Johnson & Johnson Innovation, Johnson & Johnson
Keld Flintholm Jørgensen, EVP & CBO, Lundbeck
Moderator: Christine Lind, VP Commercial, NDA Group

The LSX channel features sessions from LSX events, where our mission is to connect senior #biotech, #medtech & #healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.

Subscribe to our channel for more videos.

Follow us on Twitter: https://twitter.com/LSXLeaders

Visit us at www.lsxleaders.com